Open House - Global Healthcare 2022: The Open 100 | Edison Group

Dr. Sean Hall, Chief Executive Officer, Medlab

Sean founded Medlab in August 2012; he has over 20 years' experience in nutraceutical sales and development, as well as early drug discovery in Australia, Asia and the US. Sean has led and inspired his teams to author multiple patents, write peer-reviewed articles and deliver lectures at scientific conferences. His passion is leading his researchers into novel areas and strong commercialisation opportunities.Prior Sean was a founder of FIT-BioCeuticals. Under his management and guidance, BioCeuticals became the most innovative, research-driven, practitioner brand in Australia. For his sale of FIT-BioCeuticals to Blackmores in 2012, Sean was nominated as a finalist in the inaugural Australian Exit CEO of the Year Award. Sean is a Medical Doctor with an MBA in clinical pharmaceutical management and focuses on the research to pioneer innovation and commercialisation. Sean is an active member of Medicines Australia, the European Medical Association, the American Federation for Medical Researcher, The World Medical Association, A4M and Special Operations Medical Association.

Dr. James Garner, Chief Executive Officer & Executive Director, Kazia

Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore. Dr Garner is a member of the Australian Institute of Company Directors.

Martin Lehr, Co-Founder and Chief Executive Officer, Context

Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr serves on the Boards of Praesidia Biologics and CureDuchenne Ventures. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. Martin is a Director of BioBreak, a biotech executive peer networking group with over 2,500 active members across the United States, and an Advisory Board Member of Life Science Cares and Life Science Leader magazine. Mr. Lehr holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

Amro Albanna, Co-Founder, Chairman, and CEO, Aditxt, Inc.

Amro co-founded Aditxt in September 2017, focusing on advancing some of the most promising biotechnologies around the health of the immune system. The company has grown to become a global leader developing a new class of therapeutics designed to retrain the immune system to potentially address organ rejection, autoimmunity, and allergies. Prior to Aditxt, Amro founded multiple companies ranging from promising innovations including nano-sensors for detecting environmental gases, volatile compounds designed to interfere with mosquitoes’ smell neurons responsible for the protection against mosquito-borne diseases, and semiconductor sensors chips combining GPS & wireless technologies. Amro earned his Bachelor of Science Degree in Business Administration and Computer Information Systems from California State University, San Bernardino. He continued his informal education at California State Long Beach and Harvard Medical School (HMX online).

Dr. Tim Guilliams, Co-Founder and Chief Executive, Healx

Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using AI to accelerate treatments for rare diseases. He is the Co-Founder and Chief Executive of Healx, the mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. In this role, Tim has been listed in The Sunday Times Maserati 100 list of entrepreneurs in 2019, was featured in The Telegraph’s Tech 100 in 2019, and was named one as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020. Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease. Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.

Michael Chen, Founder & CTO, Nuclera

Michael is first and foremost a scientist. He completed his PhD at the University of Cambridge and the National Institutes of Health where he used X-ray crystallography to study the interactions of proteins and nucleic acids at near-atomic level resolution. Prior to his PhD, Michael completed his BSc at the Georgia Institute of Technology in Chemistry. Michael and his fellow co-founders met in the lab during their PhD training. Their first-hand experience at the benchtop advances the product ethos at Nuclera of design by scientists for scientists. Alongside his team, Michael works to ensure Nuclera's products make proteins, and ultimately biology, accessible. Michael has numerous patents and publications, including in Nature. He is a Goldwater Scholar and a recipient of the Scaringe Award. Outside of work, he enjoys hiking, traveling, and watching science fiction shows.